Key result
The visfatin/PBEF -948C>A polymorphism was significantly associated with type 2 diabetes, with a minor allele frequency of 0.157 in cases versus 0.119 in controls (p=0.021).
Why the study?
Are visfatin/PBEF gene polymorphisms associated with an increased risk of type 2 diabetes and low-grade inflammation?
Case-Control (n=1,764)
Are visfatin/PBEF gene polymorphisms associated with an increased risk of type 2 diabetes and low-grade inflammation?
The visfatin/PBEF -948C>A polymorphism is associated with increased susceptibility to type 2 diabetes and elevated markers of chronic low-grade inflammation.
May flag genetic susceptibility to type 2 diabetes; leaves open causal role in low-grade inflammation and needs prospective validation.
Visfatin (also known as pre-B cell colony-enhancing factor, or PBEF) is a pro-inflammatory adipokine expressed predominantly in visceral fat. We investigated whether polymorphisms at the visfatin/PBEF locus influence the risk of type 2 diabetes (T2D). Linkage disequilibrium analysis of 52 single nucleotide polymorphisms spanning the entire gene (34.7 kb) plus 20.5 kb of the upstream region and 25.5 kb of the downstream region revealed a single haplotype block that could be tagged by seven single nucleotide polymorphisms. These seven tags were typed in a group of T2D patients (n = 814) and a group of non-diabetic controls (n = 320) of white origin. A significant association was observed at -948C>A, with minor allele frequencies of 0.157 in T2D cases and 0.119 in non-diabetic controls (p = 0.021). In a non-diabetic population (n = 630), the same -948 allele that conferred increased risk of T2D was significantly associated with higher plasma levels of fibrinogen and C-reactive protein (p = 0.0022 and 0.0038, respectively). However, no significant associations were observed with BMI, waist circumference, serum glucose levels, or fasting insulin levels. Our findings suggest that the visfatin/PBEF gene may play a role in determining T2D susceptibility, possibly by modulating chronic, low-grade inflammatory responses.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2006) conducted a case-control in Type 2 diabetes (n=1,764). Visfatin/PBEF -948C>A polymorphism vs. Non-diabetic controls was evaluated on Type 2 diabetes susceptibility (minor allele frequency) (p=0.021). The visfatin/PBEF -948C>A polymorphism was significantly associated with type 2 diabetes, with a minor allele frequency of 0.157 in cases versus 0.119 in controls (p=0.021).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: